Genetic Engineering Could Make Allo SCTs Safer and More Effective

A new study indicates that certain donor cells in an allogeneic stem cell transplantation could both make the procedure safer and enhance its efficacy.

Stem cell transplantations (SCT) as curative therapy for both leukemia and lymphoma have become increasingly common over the past 20 years. Allogeneic SCTs, in which the patient receives stem cells from a donor, are considered to be riskier chiefly because of the potential for graft-versus-host disease (GVHD).

In other organ transplants, the concern is that the body rejects the organ. In SCTs, the concern is that the organ (or 'graft') will reject the patient. This potentially fatal outcome is known as GVHD. Most of the current strategies to mitigate or suppress GVHD in an allogeneic SCT often limit the transplant's efficacy.

However, a discovery made by Arnab Ghosh and colleagues at Memorial Sloan-Kettering Cancer Center could change that.

TRAIL protein kills bad cells, boosts anti-tumor activity

Researchers discovered that the expression of a specific, cell-death inducing protein known as TRAIL in transplanted donor cells is crucial for an effective anti-tumor response in the recipient. They further discovered that they could engineer immune donor cells to express higher levels of the TRAIL protein, and when they did that, they found those cells were killing the cells that caused GVHD and were also boosting the anti-tumor activity of the graft.

The team has reported its findings in the Journal of Clinical Investigation, concluding, "These data indicate that TRAIL-overexpressing donor T cells could potentially enhance the curative potential of allo-HSCT by increasing GVT response and suppressing GVHD."

Source: JCI

More Articles

More Articles

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...

Secondary cancers are cancers that develop as a result of chemotherapy and/or...

One of the greatest fears of lymphoma survivors is that they’ll relapse and have to undergo treatment again. This fear is normal but awful to...

Over the years, various classification systems have been used to differentiate lymphoma types including the Rappaport Classification (used until...

If you are new to this website or are looking for guidance to a specific page, here is a list of links to articles that can help you. The "Main...

Often the one who makes the first diagnosis of Hodgkin's Lymphoma / Disease is the person affected. There are some...

Lymphedema is abnormal swelling due to the presence of excess lymphatic fluid within the tissues. This swelling occurs when the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Advances in the treatment of Hodgkin's lymphoma have resulted in remarkable survival rates, even for...